Cargando…

Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1

The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach to induce immune response against the parasite and a valuable tool for vaccine development. We have previously protected mice from toxoplasmosis by immunizing the animals with an adenovirus expressing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendes, Érica Araújo, Fonseca, Flavio G., Casério, Bárbara M., Colina, Janaína P., Gazzinelli, Ricardo Tostes, Caetano, Braulia C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654925/ https://www.ncbi.nlm.nih.gov/pubmed/23690999 http://dx.doi.org/10.1371/journal.pone.0063201

Ejemplares similares

Vaccination against Murine Toxoplasmosis Using Recombinant Toxoplasma gondii SAG3 Antigen Alone or in Combination with Quil A
por: Lee, Young-Ha, et al.
Publicado: (2007)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii
por: Lu, Gang, et al.
Publicado: (2014)

SAG4 DNA and Peptide Vaccination Provides Partial Protection against T. gondii Infection in BALB/c Mice
por: Zhou, Jian, et al.
Publicado: (2017)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Evaluation of Recombinant SAG1, SAG2, and SAG3 Antigens for Serodiagnosis of Toxoplasmosis
por: Khanaliha, Khadijeh, et al.
Publicado: (2014)

Expression of in vivo biotinylated recombinant antigens SAG1 and SAG2A from Toxoplasma gondii for improved seroepidemiological bead-based multiplex assays
por: Klein, Sandra, et al.
Publicado: (2020)

Attenuated recombinant Bordetella pertussis as live vaccines for the protection against homologous and heterologous diseases
por: Locht, C., et al.
Publicado: (1997)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Compound DNA vaccine encoding SAG1/ SAG3 with A(2)/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii
por: Cong, Hua, et al.
Publicado: (2013)

Multicomponent DNA vaccine-encoding Toxoplasma gondii GRA1 and SAG1 primes: anti-Toxoplasma immune response in mice
por: Wu, Xiao-Nan, et al.
Publicado: (2012)

Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii
por: Wang, Yanhua, et al.
Publicado: (2014)

Evaluation of Recombinant SAG1 Protein for Detection of Toxoplasma gondii Specific Immunoglobulin M by ELISA Test
por: Jalallou, N, et al.
Publicado: (2012)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1
por: Wang, Yanhua, et al.
Publicado: (2013)

A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
por: Pereira, Isabela Resende, et al.
Publicado: (2015)

Enzyme-linked immunosorbent assays using recombinant TgSAG2 and NcSAG1 to detect Toxoplasma gondii and Neospora caninum-specific antibodies in domestic animals in Turkey
por: ZHOU, Mo, et al.
Publicado: (2016)

Recombinant SAG1 Antigen to Detect Toxoplasma gondii Specific Immunoglobulin G in Human Sera by ELISA Test
por: Jalallou, N, et al.
Publicado: (2010)

Evaluation of Immunogenic Effect of Toxoplasma gondii Recombinant SAG-1 Antigen with Propranolol as Adjuvant in BALB/c Mice
por: Abasi, Esmaeil, et al.
Publicado: (2019)

Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis
por: Choi, Won Hyung, et al.
Publicado: (2020)

Co-Immunization with DNA Vaccines Expressing SABP1 and SAG1 Proteins Effectively Enhanced Mice Resistance to Toxoplasma gondii Acute Infection
por: Sang, Xiaoyu, et al.
Publicado: (2023)

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes
por: Fraleigh, Nya L., et al.
Publicado: (2019)

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges
por: Lee, Andrew Chak-Yiu, et al.
Publicado: (2021)

HOMOLOGOUS AND HETEROLOGOUS PROTECTION IN MICE VACCINATED WITH THE TWO TYPES OF MOUSE TYPHOID BACILLUS
por: Pritchett, Ida W.
Publicado: (1924)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Toxoplasma gondii SAG2, SAG3 and GRA6 alleles and single nucleotide polymorphism in congenital infections with known parasite load and clinical outcome
por: Targa, Lília Spaleta, et al.
Publicado: (2023)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Transgenic Eimeria tenella as a vaccine vehicle: expressing TgSAG1 elicits protective immunity against Toxoplasma gondii infections in chickens and mice
por: Tang, Xinming, et al.
Publicado: (2016)

Boosting Mouse Defense against Lethal Toxoplasma gondii Infection with Full-Length and Soluble SAG1 Recombinant Protein
por: Li, Xiang, et al.
Publicado: (2023)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay
por: Orlandi, Chiara, et al.
Publicado: (2023)

Stimulation of homologous recombination in plants expressing heterologous recombinases
por: Barakate, Abdellah, et al.
Publicado: (2020)

Primary structure of mature SAG1 gene of an Indonesian Toxoplasma gondii and comparison with other strains
por: Hartati, Sri, et al.
Publicado: (2006)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
por: Mrak, Daniel, et al.
Publicado: (2022)

In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
por: Hosseininejad, Zahra, et al.
Publicado: (2023)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

First trials of oral vaccination with rabies SAG2 dog baits in Morocco
por: Darkaoui, Sami, et al.
Publicado: (2014)

Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine
por: Roediger, Elizabeth K, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_lbecdea61jl5huodnlgnblir4r